HK1198629A1 - 高負載的水溶性載體連接的前藥 - Google Patents
高負載的水溶性載體連接的前藥Info
- Publication number
- HK1198629A1 HK1198629A1 HK14112148.0A HK14112148A HK1198629A1 HK 1198629 A1 HK1198629 A1 HK 1198629A1 HK 14112148 A HK14112148 A HK 14112148A HK 1198629 A1 HK1198629 A1 HK 1198629A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- soluble carrier
- loading water
- linked prodrugs
- prodrugs
- linked
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
Landscapes
- Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11177405 | 2011-08-12 | ||
| PCT/EP2012/065731 WO2013024047A1 (en) | 2011-08-12 | 2012-08-10 | High-loading water-soluble carrier-linked prodrugs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1198629A1 true HK1198629A1 (zh) | 2015-05-22 |
Family
ID=46690492
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK14112148.0A HK1198629A1 (zh) | 2011-08-12 | 2014-12-02 | 高負載的水溶性載體連接的前藥 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20140296257A1 (zh) |
| EP (1) | EP2741779A1 (zh) |
| AU (1) | AU2012296949B2 (zh) |
| CA (1) | CA2843875C (zh) |
| HK (1) | HK1198629A1 (zh) |
| WO (1) | WO2013024047A1 (zh) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2882563C (en) | 2012-08-21 | 2022-11-29 | Eric Hryhorenko | Antibodies to risperidone haptens and use thereof |
| CN104837838A (zh) * | 2012-08-21 | 2015-08-12 | 詹森药业有限公司 | 帕潘立酮半抗原 |
| JP2015527365A (ja) | 2012-08-21 | 2015-09-17 | オルソ−クリニカル ダイアグノスティクス，インコーポレイティド | パリペリドンに対する抗体及びその使用 |
| PL2888234T3 (pl) | 2012-08-21 | 2018-07-31 | Janssen Pharmaceutica Nv | Hapteny arypiprazolu i ich zastosowanie w testach immunologicznych |
| AU2013305879B2 (en) | 2012-08-21 | 2017-10-12 | Saladax Biomedical Inc. | Antibodies to aripiprazole and use thereof |
| WO2014031603A1 (en) | 2012-08-21 | 2014-02-27 | Ortho-Clinical Diagnostics, Inc | Antibodies to paliperidone haptens and use thereof |
| EP3933406A3 (en) | 2012-08-21 | 2022-04-20 | Janssen Pharmaceutica NV | Antibodies to risperidone and use thereof |
| AU2013305970B2 (en) | 2012-08-21 | 2017-08-17 | Saladax Biomedical Inc. | Antibodies to aripiprazole haptens and use thereof |
| JP6290243B2 (ja) | 2012-12-07 | 2018-03-07 | アセンディス ファーマ エー／エス | 担体連結プロスタノイドプロドラッグ |
| JP6491203B2 (ja) | 2013-10-25 | 2019-03-27 | インスメッド インコーポレイテッド | プロスタサイクリン化合物、組成物およびその使用方法 |
| EP3068438A1 (en) | 2013-11-11 | 2016-09-21 | Ascendis Pharma Relaxin Division A/S | Relaxin prodrugs |
| CA2955569C (en) | 2014-08-06 | 2023-02-14 | Ascendis Pharma A/S | Prodrugs comprising an aminoalkyl glycine linker |
| WO2016081658A1 (en) | 2014-11-18 | 2016-05-26 | Insmed Incorporated | Methods of manufacturing treprostinil and treprostinil derivative prodrugs |
| CN104458937B (zh) * | 2014-11-20 | 2017-02-22 | 北京京科泰来科技有限公司 | 一种丁酸氯维地平脂肪乳有关物质检测方法 |
| EP3303365A4 (en) | 2015-05-29 | 2019-04-24 | Ascendis Pharma Inc. | PRODRUGS WITH A PYROGLUTAMATE LINKER |
| US10444250B2 (en) | 2015-12-17 | 2019-10-15 | Janssen Pharmaceutica Nv | Antibodies to risperidone and use thereof |
| RS63793B1 (sr) | 2016-01-08 | 2022-12-30 | Ascendis Pharma Growth Disorders As | Cnp prolekovi kod kojih je nosač povezan sa cikličnom komponentom |
| IL259829B2 (en) | 2016-01-08 | 2023-03-01 | Ascendis Pharma Growth Disorders As | Controlled-release cnp agonists with low npr–c binding |
| MX2018008061A (es) | 2016-01-08 | 2018-08-23 | Ascendis Pharma Growth Disorders As | Profarmacos de peptido natriuretico tipo c (cnp) con porciones portadoras grandes. |
| AU2017205273C1 (en) | 2016-01-08 | 2022-12-01 | Ascendis Pharma Growth Disorders A/S | Controlled-release CNP agonists with reduced side-effects |
| CA3008015A1 (en) | 2016-01-08 | 2017-07-13 | Ascendis Pharma Growth Disorders A/S | Controlled-release c-type natriuretic peptide agonists with increased neutral endopeptidase stability |
| NZ743488A (en) | 2016-01-08 | 2023-02-24 | Ascendis Pharma Growth Disorders As | Controlled-release cnp agonists with low initial npr-b activity |
| CA3030376A1 (en) | 2016-07-13 | 2018-01-18 | Ascendis Pharma A/S | Conjugation method for carrier-linked prodrugs |
| US20190204312A1 (en) * | 2016-09-16 | 2019-07-04 | Technische Universität München | Magnetic particle-binding peptides |
| KR20230066147A (ko) | 2016-09-29 | 2023-05-12 | 아센디스 파마 그로우쓰 디스오더스 에이/에스 | 조절 방출 cnp 아고니스트를 사용한 병용 요법 |
| CN106818805A (zh) * | 2016-12-27 | 2017-06-13 | 东莞市联洲知识产权运营管理有限公司 | 一种天然乙酰胆碱酯酶抑制剂及其杀虫应用 |
| KR20200047557A (ko) | 2017-08-04 | 2020-05-07 | 오비드 테라퓨틱스 인크. | 당뇨병 및 관련 질환들의 치료에서 가복사돌의 사용 |
| MX2021000677A (es) | 2018-07-19 | 2021-03-25 | Starpharma Pty Ltd | Dendrimero terapeutico. |
| US12071517B2 (en) | 2018-07-19 | 2024-08-27 | Starpharma Pty Ltd. | Therapeutic dendrimer |
| KR20210130750A (ko) | 2019-02-11 | 2021-11-01 | 아센디스 파마 그로우쓰 디스오더스 에이/에스 | Cnp 접합체의 건조 약학 제제 |
| US11471497B1 (en) | 2019-03-13 | 2022-10-18 | David Gordon Bermudes | Copper chelation therapeutics |
| JP7455144B2 (ja) | 2019-04-29 | 2024-03-25 | インスメッド インコーポレイテッド | トレプロスチニルプロドラッグの乾燥粉末組成物およびその使用方法 |
| EP3986477A1 (en) | 2019-06-21 | 2022-04-27 | Ascendis Pharma A/S | CONJUGATES OF pi-ELECTRON-PAIR-DONATING HETEROAROMATIC NITROGEN-COMPRISING COMPOUNDS |
| EP3986471A1 (en) | 2019-06-21 | 2022-04-27 | Ascendis Pharma A/S | Conjugates of an electron-donating nitrogen or tertiary amine comprising compounds |
| EP3986472A1 (en) | 2019-06-21 | 2022-04-27 | Ascendis Pharma A/S | Conjugates of heteroaromatic nitrogen-comprising compounds |
| CN110652596B (zh) * | 2019-11-06 | 2020-11-03 | 吉林大学 | 一种雷公藤红素纳米粒子、其制备方法及应用 |
| EP4084872A1 (en) | 2020-01-03 | 2022-11-09 | Ascendis Pharma A/S | Conjugates undergoing intramolecular rearrangements |
| EP4192508A1 (en) | 2020-08-05 | 2023-06-14 | Ascendis Pharma A/S | Conjugates comprising reversible linkers and uses thereof |
| US11291627B1 (en) * | 2020-09-24 | 2022-04-05 | Ocular Therapeutix, Inc. | Sustained release biodegradable intracanalicular inserts comprising a hydrogel and cyclosporine |
| EP4216929A1 (en) * | 2020-09-24 | 2023-08-02 | Ocular Therapeutix, Inc. | Sustained release biodegradable intracanalicular inserts comprising a hydrogel and an active agent |
| BR112023018802A2 (pt) | 2021-04-01 | 2023-10-31 | Ascendis Pharma As | Uso de hormônio de crescimento de ação prolongada para o tratamento de doenças induzidas por inflamação |
| CA3236278A1 (en) | 2021-12-13 | 2023-06-22 | Kennett Sprogoe | Effective doses of cnp conjugates |
| WO2023227505A1 (en) | 2022-05-23 | 2023-11-30 | Ascendis Pharma Growth Disorders A/S | Liquid pharmaceutical formulations of cnp compounds |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6624142B2 (en) | 1997-12-30 | 2003-09-23 | Enzon, Inc. | Trimethyl lock based tetrapartate prodrugs |
| US6413507B1 (en) | 1999-12-23 | 2002-07-02 | Shearwater Corporation | Hydrolytically degradable carbamate derivatives of poly (ethylene glycol) |
| AU2001257577A1 (en) | 2000-02-28 | 2001-09-03 | Shearwater Corporation | Water-soluble polymer conjugates of artelinic acid |
| US7097856B2 (en) * | 2000-09-29 | 2006-08-29 | The Regents Of The University Of California | Dendrimeric support or carrier macromolecule |
| AU2003226166A1 (en) | 2002-04-04 | 2003-10-20 | Enzon, Inc. | Polymeric acyl derivatives of indoles |
| ES2512499T3 (es) | 2003-04-08 | 2014-10-24 | Yeda Research And Development Co., Ltd. | Fármacos pegilados reversibles |
| EP2626083A1 (en) | 2003-09-17 | 2013-08-14 | Nektar Therapeutics | Multi-arm polymer prodrugs |
| CA2824093C (en) | 2004-03-23 | 2016-10-25 | Complex Biosystems Gmbh | Polymeric prodrug with a self-immolative linker |
| AT7634U1 (de) | 2004-06-29 | 2005-06-27 | Binder Co Ag | Detektiervorrichtung und sortiervorrichtung |
| GB2427360A (en) | 2005-06-22 | 2006-12-27 | Complex Biosystems Gmbh | Aliphatic prodrug linker |
| CA2662962A1 (en) | 2006-09-15 | 2008-03-20 | Enzon Pharmaceuticals, Inc. | Polyalkylene oxides having hindered ester-based biodegradable linkers |
| US8906847B2 (en) | 2008-02-01 | 2014-12-09 | Ascendis Pharma A/S | Prodrug comprising a drug linker conjugate |
| KR101671537B1 (ko) | 2008-08-11 | 2016-11-01 | 넥타르 테라퓨틱스 | 다분지형 중합체 알카노에이트 컨쥬게이트 |
| WO2010039861A2 (en) | 2008-09-30 | 2010-04-08 | The Regents Of The University Of Michigan | Dendrimer conjugates |
| WO2010075423A2 (en) | 2008-12-23 | 2010-07-01 | The Regents Of The University Of Michigan | Dendrimer based modular platforms |
| EP2459225A1 (en) * | 2009-07-31 | 2012-06-06 | Ascendis Pharma A/S | Carrier linked pramipexole prodrugs |
| EP2459227B1 (en) | 2009-07-31 | 2021-03-17 | Ascendis Pharma A/S | Prodrugs containing an aromatic amine connected by an amide bond to a carrier |
-
2012
- 2012-08-10 CA CA2843875A patent/CA2843875C/en active Active
- 2012-08-10 US US14/237,429 patent/US20140296257A1/en not_active Abandoned
- 2012-08-10 EP EP12748192.7A patent/EP2741779A1/en active Pending
- 2012-08-10 AU AU2012296949A patent/AU2012296949B2/en active Active
- 2012-08-10 WO PCT/EP2012/065731 patent/WO2013024047A1/en active Application Filing
-
2014
- 2014-12-02 HK HK14112148.0A patent/HK1198629A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20140296257A1 (en) | 2014-10-02 |
| EP2741779A1 (en) | 2014-06-18 |
| AU2012296949A1 (en) | 2014-02-20 |
| AU2012296949B2 (en) | 2016-09-15 |
| WO2013024047A1 (en) | 2013-02-21 |
| CA2843875C (en) | 2020-01-07 |
| CA2843875A1 (en) | 2013-02-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1198629A1 (zh) | 高負載的水溶性載體連接的前藥 | |
| HK1198359A1 (zh) | 載體連接的曲羅尼爾前藥 | |
| HK1198630A1 (zh) | 蛋白質載體連接的前藥 | |
| HK1198628A1 (zh) | 聚合的高度支化的載體連接的前藥 | |
| EP2722937A4 (en) | CONNECTOR | |
| EP2725661A4 (en) | CONNECTOR | |
| EP2667458A4 (en) | INTERCONNECTS | |
| EP2762194A4 (en) | CONNECTION | |
| EP3604696C0 (en) | WEAR ARRANGEMENT | |
| EP2779317A4 (en) | INTERCONNECTS | |
| EP2787386A4 (en) | MASK | |
| EP2683038A4 (en) | INTERCONNECTS | |
| EP2654136A4 (en) | CONNECTOR | |
| EP2725663A4 (en) | INTERCONNECTS | |
| EP2665133A4 (en) | CONNECTOR | |
| PT2543408T (pt) | Máscara de assistência respiratória | |
| EP2712031A4 (en) | INTERCONNECTS | |
| EP2701241A4 (en) | INTERCONNECTS | |
| GB201106267D0 (en) | Connector | |
| EP2768083A4 (en) | CONNECTOR | |
| EP2686599A4 (en) | QUICK COUPLING | |
| EP2712034A4 (en) | INTERCONNECTS | |
| EP2750252A4 (en) | CONNECTOR | |
| HK1215190A1 (zh) | 載體連接型前列腺素類前藥 | |
| EP2673851A4 (en) | CONNECTOR |